A man who almost died from a blood clot is to launch a product which could save the NHS millions of pounds a year.
Paul Westerman suffered a massive pulmonary embolism – the result of a deep vein thrombosis – in 2011 and has spent the last eight years researching the condition and working with experts within respiratory and thrombotic medicine.
Now the 51-year-old, in conjunction with leading clinicians and a world- renowned product designer, has created the RBR legflow – which helps improve the venous blood flow in the lower limbs of individuals when seated.
Paul said: “DVT and PE costs the NHS over £200 million every single year. But clinical research reveals that many blood clots are entirely preventable.
“With this in mind, we would like to see the RBR leg flow available in every hospital, care home, work place, air plane, gaming environment, and environment where an individual is likely to be sedentary for over an hour.” are approved by the FDA and EPA. The RBR leg flow was created with Mr Westerman added: “Using an the input of Professor Richard Beasley, active antimicrobial ingredient in director of the Medical Research the RBR legflow has enabled us to Institute of New Zealand and a world differentiate our product from those authority on respiratory medicine who has 
undertaken ground-breaking research of ‘e-thrombosis’.
He said: “Research from the MRINZ has shown that this device markedlyincreases lower limb venous blood flow,thereby potentially reducing the risk of blood clots, in people who sit for long periods at work or with long-distance air travel.”
As part of its design, the RBR legflow is manufactured with an antimicrobial ingredient which offers excellent protection against bacteria, biofilm, fungi and mould, and has no adverse effect on the RBR legflo properties.
This antimicrobial element remains effective for the lifetime of the product and all the active components used of our competitors and dramatically reduce the risk of cross-infection.
“This means the RBR legflow is theperfect solution for the prevention, care and treatment of deep vein thrombosis and pulmonary embolism within the NHS and other health care providers globally.”
